Back to News
Market Impact: 0.35
Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment
Source: Nasdaq
Regulation & LegislationHealthcare & BiotechProduct LaunchesCompany Fundamentals
Milestone Pharmaceuticals said China’s NMPA approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. The approval is described as the first regulatory authorization for e... (ongoing from article text), a meaningful milestone that supports commercialization prospects in the China market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
MIST0.75
More News
- Nvidia CEO Jensen Huang emerges as Trump's top ally in AI safety debate
- Williams-Sonoma's stock has soared in a sluggish housing market. Here's how it won over Wall Street
- Franklin CEO Says AI Payoff Remains Unclear
- Budget airline king Bill Franke warms to first-class seats and premium upgrades
- Top Wall Street analysts find these 3 stocks attractive as long-term investments
- Dating apps are trying to cure swiping fatigue with pickleball, trivia nights, and fewer chats